Humacyte (NASDAQ:HUMA) Earns Buy Rating from D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They currently have a $25.00 target price on the stock.

Other analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research report on Wednesday, March 12th. Benchmark restated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Humacyte presently has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Trading Up 0.5 %

HUMA opened at $2.01 on Wednesday. The business has a 50 day moving average of $3.66 and a 200-day moving average of $4.53. The stock has a market capitalization of $252.98 million, a price-to-earnings ratio of -1.50 and a beta of 1.36. Humacyte has a 1-year low of $1.96 and a 1-year high of $9.97.

Institutional Investors Weigh In On Humacyte

Institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Humacyte by 85.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 202,825 shares of the company’s stock worth $1,024,000 after buying an additional 93,283 shares in the last quarter. Waverly Advisors LLC lifted its holdings in shares of Humacyte by 331.9% during the fourth quarter. Waverly Advisors LLC now owns 274,579 shares of the company’s stock valued at $1,387,000 after acquiring an additional 211,009 shares during the period. Woodline Partners LP boosted its stake in shares of Humacyte by 235.7% in the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock valued at $14,386,000 after purchasing an additional 2,000,268 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Humacyte in the 4th quarter worth about $132,000. Finally, ProShare Advisors LLC increased its position in shares of Humacyte by 30.4% during the 4th quarter. ProShare Advisors LLC now owns 30,852 shares of the company’s stock worth $156,000 after purchasing an additional 7,188 shares in the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.